MA38406A1 - Virus de la maladie de newcastle et leurs utilisations - Google Patents

Virus de la maladie de newcastle et leurs utilisations

Info

Publication number
MA38406A1
MA38406A1 MA38406A MA38406A MA38406A1 MA 38406 A1 MA38406 A1 MA 38406A1 MA 38406 A MA38406 A MA 38406A MA 38406 A MA38406 A MA 38406A MA 38406 A1 MA38406 A1 MA 38406A1
Authority
MA
Morocco
Prior art keywords
newcastle disease
immune cell
viruses
disease virus
compositions
Prior art date
Application number
MA38406A
Other languages
English (en)
Other versions
MA38406B1 (fr
Inventor
Peter Palese
Sastre Adolfo Garcia
Dmitriy Zamarin
James Allison
Jedd D Wolchok
Original Assignee
Icahn School Med Mount Sinai
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Memorial Sloan Kettering Cancer Center filed Critical Icahn School Med Mount Sinai
Publication of MA38406A1 publication Critical patent/MA38406A1/fr
Publication of MA38406B1 publication Critical patent/MA38406B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des virus chimériques de la maladie de newcastle génétiquement modifiés pour exprimer un agoniste d'un signal de costimulation d'une cellule immunitaire et des compositions comprenant de tels virus. L'invention concerne également un virus chimérique de la maladie de newcastle génétiquement modifié pour exprimer un antagoniste d'un signal inhibiteur d'une cellule immunitaire et des compositions comprenant de tels virus. Les virus chimériques de la maladie de newcastle et les compositions sont utiles dans le traitement du cancer. De plus, l'invention concerne des méthodes de traitement du cancer comprenant l'administration de virus de la maladie de newcastle en combinaison avec un agoniste d'un signal de costimulation d'une cellule immunitaire et/ou un antagoniste d'un signal inhibiteur d'une cellule immunitaire.
MA38406A 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations MA38406B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782994P 2013-03-14 2013-03-14
PCT/US2014/020299 WO2014158811A1 (fr) 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38406A1 true MA38406A1 (fr) 2017-12-29
MA38406B1 MA38406B1 (fr) 2020-03-31

Family

ID=51527979

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38406A MA38406B1 (fr) 2013-03-14 2014-03-04 Virus de la maladie de newcastle et leurs utilisations

Country Status (28)

Country Link
US (5) US20160015760A1 (fr)
EP (1) EP2968525A4 (fr)
JP (4) JP6596411B2 (fr)
KR (1) KR102222157B1 (fr)
CN (3) CN111218429A (fr)
AP (1) AP2015008685A0 (fr)
AU (2) AU2014241843B2 (fr)
BR (1) BR112015021414B1 (fr)
CA (1) CA2905272A1 (fr)
CL (2) CL2015002532A1 (fr)
CR (1) CR20150465A (fr)
DO (1) DOP2015000227A (fr)
EA (1) EA038981B1 (fr)
GE (2) GEAP201913952A (fr)
HK (1) HK1216618A1 (fr)
IL (2) IL241120A0 (fr)
MA (1) MA38406B1 (fr)
MD (1) MD4655C1 (fr)
MX (2) MX375431B (fr)
MY (1) MY180687A (fr)
NI (1) NI201500131A (fr)
NZ (1) NZ711946A (fr)
PE (1) PE20151921A1 (fr)
PH (1) PH12015502087A1 (fr)
SG (2) SG11201507412SA (fr)
TN (1) TN2015000353A1 (fr)
WO (1) WO2014158811A1 (fr)
ZA (1) ZA201506192B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2987856B1 (fr) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Virus chimériques de la maladie de newcastle et utilisations de ceux-ci
EP2968525A4 (fr) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai Virus de la maladie de newcastle et leurs utilisations
HUE042382T2 (hu) * 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3110443A4 (fr) 2014-02-27 2017-11-15 Viralytics Limited Thérapie combinée pour le traitement du cancer
CA2942245C (fr) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reduction des niveaux ou de l'activite systemiques des lymphocytes t regulateurs en vue du traitement de maladies et de lesions touchant le snc
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP4205749A1 (fr) 2014-07-31 2023-07-05 Novartis AG Cellules contenant un récepteur d'antigène chimérique optimisé en sous-ensemble
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
JP6692834B2 (ja) 2015-02-09 2020-05-13 スリングショット バイオサイエンシーズ， インコーポレイテッド 調整可能な光学特性を有するヒドロゲル粒子およびその使用の方法
CN105985966B (zh) * 2015-03-06 2024-08-16 普莱柯生物工程股份有限公司 基因vii型新城疫病毒株、其疫苗组合物、制备方法及应用
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
EP4643874A3 (fr) 2015-12-22 2026-02-11 Novartis AG Récepteur antigénique chimérique (car) de mésothéline et anticorps contre un inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
EP3487878A4 (fr) 2016-07-20 2020-03-25 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (fr) 2017-04-28 2020-03-04 Novartis AG Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3630144A4 (fr) 2017-05-25 2021-03-31 University of Central Florida Research Foundation, Inc. Nouveaux virus oncolytiques pour sensibiliser des cellules tumorales à la destruction par des cellules tueuses naturelles
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3801769A1 (fr) 2018-05-25 2021-04-14 Novartis AG Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
CN112739359A (zh) * 2018-07-13 2021-04-30 西奈山伊坎医学院 Apmv及其用于治疗癌症的用途
WO2020037215A1 (fr) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Virus de la maladie de newcastle recombinés et leurs utilisations pour la prévention d'une maladie à rsv ou d'une maladie à métapneumovirus humain
JP2022512541A (ja) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Ｐｄ－１系キメラタンパク質を含む併用療法
WO2020069409A1 (fr) 2018-09-28 2020-04-02 Novartis Ag Polythérapies à base de récepteur antigénique chimérique (car) cd19 et de car cd22
WO2020069405A1 (fr) 2018-09-28 2020-04-02 Novartis Ag Thérapies par récepteur antigénique chimérique (car) de cd22
WO2020075672A1 (fr) * 2018-10-09 2020-04-16 バイオコモ株式会社 Agent anticancéreux, composition pharmaceutique pour le traitement du cancer et kit
CN109627336A (zh) * 2018-12-20 2019-04-16 南京昂科利医药科技创新研究院有限公司 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用
CA3125370A1 (fr) * 2019-01-29 2020-08-06 Arno Thaller Virus de la maladie de newcastle oncolytiques recombinants a activite accrue
WO2020185739A1 (fr) 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anticorps anti-icos pour le traitement du cancer
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
EP3725370A1 (fr) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative
CN110564766A (zh) * 2019-09-20 2019-12-13 华农（肇庆）生物产业技术研究院有限公司 一种全基因组表达载体pBR322-DHN3的制备方法
CN110672844A (zh) * 2019-10-29 2020-01-10 华中科技大学 一种新城疫病毒抗体磁免疫化学发光检测试剂盒及其应用
JP2022554270A (ja) 2019-11-05 2022-12-28 ジョンス セラピューティクス， インコーポレイテッド 抗ｐｄ－１抗体による癌を治療する方法
EP4065157A1 (fr) 2019-11-26 2022-10-05 Novartis AG Récepteurs antigéniques chimériques pour cd19 et cd22 et leurs utilisations
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4512828A3 (fr) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Méthodes d'enrichissement et de croisement ex vivo de cellules t tumorales réactives et compositions connexes
WO2021229270A1 (fr) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vaccin recombinant contre la covid-19 à vecteur viral
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
EP4215214A4 (fr) * 2020-09-16 2024-07-03 Osaka University Agent thérapeutique contre le cancer, immunostimulant et procédé de dépistage pour substance anticancéreuse
CA3198447A1 (fr) 2020-11-13 2022-05-19 Novartis Ag Polytherapies avec des cellules exprimant un recepteur antigenique chimerique (car)
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR102476901B1 (ko) * 2021-08-06 2022-12-14 리벤텍 주식회사 대장암 세포 특이적 감염 뉴캐슬병 바이러스를 이용한 대장암 치료용 암용해성 바이러스 및 이를 이용한 대장암 치료용 조성물
AU2022376541A1 (en) 2021-10-29 2024-04-18 Slingshot Biosciences, Inc. Hydrogel particles as feeder cells and as synthetic antigen presenting cells
CN119907921A (zh) 2022-05-05 2025-04-29 弹弓生物科学公司 用于血液学的作为红细胞模拟物的工程化颗粒和含有工程化颗粒的组合物
CN120712108A (zh) 2022-10-26 2025-09-26 弹弓生物科学公司 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法
WO2025049609A1 (fr) 2023-08-29 2025-03-06 Slingshot Biosciences, Inc. Mimétiques de cellules souches cd34
WO2025116613A1 (fr) * 2023-11-29 2025-06-05 주식회사 카브 Composition pharmaceutique pour le traitement du cancer, comportant des vecteurs viraux recombinés de la maladie de newcastle

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
CA2161671A1 (fr) 1993-04-30 1994-11-10 Robert M. Lorence Methodes pour le traitement et la detection de cancers a l'aide de virus
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
CN1200037A (zh) 1995-10-17 1998-11-25 韦恩州立大学 鸡白细胞介素－15及其用途
WO1998002530A1 (fr) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production de vaccins a base de virus respiratoire syncytial attenue, a partir de sequences nucleotidiques clonees
CA2265554A1 (fr) 1996-09-27 1998-04-02 American Cyanamid Company Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
EP0974660A1 (fr) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Clones infectieux du virus de la maladie de Newcastle, vaccins et analyses diagnostiqués
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
ES2278621T5 (es) 1999-07-14 2011-02-02 Mount Sinai School Of Medicine Of New York University Reconstrucción in vitro de virus arn segmentados de polaridad negativa.
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
ATE305801T1 (de) 2000-01-20 2005-10-15 Univ Zuerich Inst Fuer Medizin Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
WO2001077394A1 (fr) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Methodes de criblage destinees a l'identification de proteines virales au moyen de fonctions antagonistes d'interferons et d'agents antiviraux potentiels
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
WO2002102404A1 (fr) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Utilisations de cytokines
AU2003223089A1 (en) 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
US20050191617A1 (en) 2002-06-03 2005-09-01 Makoto Inoue Pramyxovirusl vectors encoding antibody and utilization thereof
US7971030B2 (en) 2002-08-07 2011-06-28 Mmagix Technology Limited Method for using multiple processing resources which share multiple co-processor resources
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
EP3263581B2 (fr) 2005-05-17 2025-07-09 University of Connecticut Compositions et procédés d'immunomodulation dans un organisme
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
JP2007120880A (ja) 2005-10-28 2007-05-17 Mitsubishi Electric Corp クロスフローファン
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
WO2007113648A2 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008011726A1 (fr) 2006-07-27 2008-01-31 Ottawa Health Research Institute Modulation échelonnée de la réponse immunitaire dans le domaine de la thérapie oncolytique
WO2008134879A1 (fr) 2007-05-04 2008-11-13 University Health Network Immunothérapie du cancer avec l'il-2
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP2085092A1 (fr) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Paramyxovirus oncolytiques atténués encodant des cytokines aviaires
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2010042433A1 (fr) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
EP2987856B1 (fr) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Virus chimériques de la maladie de newcastle et utilisations de ceux-ci
WO2010126766A1 (fr) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interleukine-12 inductible
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
ES2598005T3 (es) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
PL2467158T3 (pl) 2009-08-21 2017-07-31 Merial, Inc. Rekombinowana szczepionka z paramyksowirusem ptaków oraz sposób jej wytwarzania i zastosowania
EP2482849B1 (fr) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Immunothérapie combinée pour le traitement du cancer
WO2011119628A2 (fr) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions et méthodes de préparation de vaccins auto-adjuvants contre microbes et tumeurs
WO2012000188A1 (fr) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Vaccin recombinant antitumoral et son procédé de production
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US20120082687A1 (en) * 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
EP2766035B1 (fr) 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Combinaison médicamenteuse comprenant de l'il-12 et un agent de blocage de molécules inhibitrices des lymphocytes t pour une thérapie anti-tumorale
WO2013112942A1 (fr) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarqueurs et polythérapies utilisant un virus oncolytique et l'immunomodulation
EP2669381A1 (fr) 2012-05-30 2013-12-04 AmVac AG Procédé pour l'expression de protéines hétérologues à l'aide d'un vecteur de virus recombinant à ARN négatifs comprenant une P proteine mutante
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US20150359853A1 (en) 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
EP2968525A4 (fr) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai Virus de la maladie de newcastle et leurs utilisations
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
PT3444271T (pt) 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
RS59756B1 (sr) 2013-08-08 2020-02-28 Cytune Pharma Kombinovana farmaceutska kompozicija
HUE042382T2 (hu) 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
EP3110443A4 (fr) 2014-02-27 2017-11-15 Viralytics Limited Thérapie combinée pour le traitement du cancer
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
ES2811974T3 (es) 2014-07-29 2021-03-15 Novartis Ag Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
EP3197911A4 (fr) 2014-09-22 2018-06-20 Intrexon Corporation Contrôle thérapeutique amélioré de formes hétérodimères et à chaîne unique de l'interleukine-12
US11377693B2 (en) 2014-12-09 2022-07-05 Merck Sharp & Dohme Llc System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技（北京）有限公司 一种用于术前介入放疗治疗肿瘤的化合物
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3328418A1 (fr) 2015-07-29 2018-06-06 Novartis AG Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
WO2017062953A1 (fr) 2015-10-10 2017-04-13 Intrexon Corporation Contrôle thérapeutique amélioré de formes d'interleukine-12 déstabilisées sensibles à la protéolyse
WO2017083291A1 (fr) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprenant des vecteurs lentiviraux exprimant l'il-12 et leurs méthodes d'utilisation
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用
CN115960966B (zh) 2016-04-29 2026-02-06 复诺健生物科技加拿大有限公司 在癌细胞中具有增强复制的hsv载体

Also Published As

Publication number Publication date
MD4655C1 (ro) 2020-06-30
CR20150465A (es) 2016-01-25
EP2968525A1 (fr) 2016-01-20
WO2014158811A1 (fr) 2014-10-02
US20140271677A1 (en) 2014-09-18
JP2023002553A (ja) 2023-01-10
CN105188746A (zh) 2015-12-23
US20180078592A1 (en) 2018-03-22
WO2014158811A8 (fr) 2015-09-17
HK1216618A1 (zh) 2016-11-25
CA2905272A1 (fr) 2014-10-02
MD20150100A2 (ro) 2016-02-29
CN111218429A (zh) 2020-06-02
CN105188746B (zh) 2020-03-17
US10251922B2 (en) 2019-04-09
EA201591740A1 (ru) 2016-06-30
IL264385A (en) 2019-02-28
MX2019008086A (es) 2019-09-10
TN2015000353A1 (en) 2017-01-03
MA38406B1 (fr) 2020-03-31
CN111172120A (zh) 2020-05-19
BR112015021414A2 (pt) 2017-07-18
JP2016517269A (ja) 2016-06-16
AU2014241843B2 (en) 2019-05-02
EA038981B1 (ru) 2021-11-17
PH12015502087B1 (en) 2016-01-18
ZA201506192B (en) 2021-01-27
GEP20196976B (en) 2019-06-10
JP6596411B2 (ja) 2019-10-23
AU2019206040A1 (en) 2019-08-01
JP2018198621A (ja) 2018-12-20
NZ711946A (en) 2020-05-29
US20180256655A1 (en) 2018-09-13
DOP2015000227A (es) 2015-11-15
AP2015008685A0 (en) 2015-08-31
AU2014241843A1 (en) 2015-09-10
PE20151921A1 (es) 2015-12-26
NI201500131A (es) 2015-10-19
MX2015011886A (es) 2016-05-31
CL2018000515A1 (es) 2018-08-03
KR102222157B1 (ko) 2021-03-03
BR112015021414B1 (pt) 2020-11-10
PH12015502087A1 (en) 2016-01-18
SG11201507412SA (en) 2015-10-29
MX375431B (es) 2025-03-06
CL2015002532A1 (es) 2016-07-15
US20180280455A1 (en) 2018-10-04
IL264385B (en) 2021-09-30
JP2020202850A (ja) 2020-12-24
GEAP201913952A (en) 2019-02-11
IL241120A0 (en) 2015-11-30
EP2968525A4 (fr) 2016-10-26
SG10201802982WA (en) 2018-06-28
MY180687A (en) 2020-12-07
US20160015760A1 (en) 2016-01-21
KR20150127164A (ko) 2015-11-16
MD4655B1 (ro) 2019-11-30

Similar Documents

Publication Publication Date Title
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX389684B (es) Anticuerpos anti tigit.
MX2019006188A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
GEP20217249B (en) Stable liquid pharmaceutical preparation
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
MA39390A1 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EP3988673A3 (fr) Variants de tnfsf15 et dcr3 associés à la maladie de crohn
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе